After two years of a successful pilot, the stage is set for the implementation of a massive cervical cancer vaccination exercise in which young girls aged 9- 15 years old throughout the country will be vaccinated against the deadly disease.
According to Dr. Robert Mayanja, the Uganda National Expanded Programme on Immunization (UNEPI) programme manager, plans to start the exercise are in high gear.
Many vaccines, such as those for Hep A and B, HPV, MMR and rabies, need several booster doses to achieve maximal immunological protection. Booster doses add to the complexity of vaccine administration, especially when used in large vaccination campaigns in the developing world.
Les autorités de santé ont décidé de changer le calendrier des vaccinations. Désormais, les bébés auront moins de piqûres.
La France va décider de rejoindre le modèle vaccinal qui existe chez ses voisins suédois, danois ou finlandais. Il prévoit notamment moins de vaccins chez les enfants lors des premières années de la vie mais la vaccination est obligatoire (diphtérie-tétanos-poliomyélite) pour garantir une bonne couverture sanitaire.
"The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999 to respond promptly, efficiently, and with scientific rigour to vaccine safety issues of potential global importance.
The Committee provides independent, authoritative, scientific advice to WHO on vaccine safety issues of global or regional concern with the potential to affect in the short or long term national immunization programmes."
If you haven't yet seen Captain Phillips, I won't spoil it. Since it's a biopic based on events recently in the news, though, I think it's fair to mention that the U.S. Navy deployed a destroyer and a SEAL team to thwart the abduction of a middle-aged guy from Massachusetts.
GlaxoSmithKline (GSK) has unveiled results of a Phase III clinical trial of its human papillomavirus (HPV) vaccine Cervarix for the prevention of cervical cancer in 9-14 year old girls.
Around 1,447 patients aged 9-25 years from across five countries were given Cervarix in the HPV-070 trial, which showed that two doses of the vaccine in girls aged 9-14 years provide an immunogenicity matching the currently licensed three-dose schedule in 15-25 year olds.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously to approve updated adult, child/adolescent and catch-up immunization schedules for the coming year during its Oct. 23-24 meeting(www.cdc.gov) in Atlanta. Committee members also discussed a number of other vaccine-related issues of interest to family physicians.
Seth Berkley, directeur de l’Alliance GAVI à Genève, montre comment le Rwanda est parvenu à vacciner 93% des adolescentes contre le papillomavirus humain, score que les pays riches sont loin d’atteindre.